Purpose: To investigate the relationship between inflammation in the vitreous and diabetic retinopathy. Methods: Vitreous samples from 21 patients with proliferative diabetic retinopathy (PDR), 21 patients with nonproliferative diabetic retinopathy (NPDR), and 21 nondiabetic patients with idiopathic epiretinal membranes (control) were studied. The interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase (MMP)-2, MMP-9, and adiponectin levels in the vitreous were detected in all samples with enzyme-linked immunosorbent assay (ELISA). Samples were stored at -80 degrees C until analyzed. Results: The TNF-alpha levels in the vitreous were not statistically significant between all groups (p>0.005). The mean IFN-gamma levels were statistically significantly higher in patients with PDR (70.98 pg/ml) and patients with NPDR (46.61 pg/ml) than in nondiabetic patients (22.02 mu g/ml). There was a difference in the IFN-gamma levels in the vitreous between patients with PDR and patients with NPDR (p0.05). There was a correlation between the IFN-gamma and TNF-alpha levels. We investigated the statistically significantly decreased levels of adiponectin in the proliferative (p<0.05) and nonproliferative (p<0.05) diabetic eyes compared to the nondiabetic eyes. Conclusions: Increased levels of IFN-gamma and TNF-alpha in the vitreous were found in patients with diabetes compared to nondiabetic patients. Decreased levels of adiponectin in the vitreous were found in patients with diabetes compared to nondiabetic patients. The data support the hypothesis that inflammation is associated with diabetic retinopathy.

Objectives: We aimed on evaluating the effect of liver dysfunction on retinal nerve fiber layer (RNFL), GCL++ (ganglion cell layer + RNFL + inner plexiform layer), central macular thickness (CMT) and subfoveal choroidal thickness (CT) measurements. Methods: Fifty two patients with primary biliary cirrhosis (PBC group) and 61 healthy individuals (control group) were included in our study. Blood alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), alkaline phosphatase (ALP), total bilirubin, albumin, prothrombin time results as the international normalized ratio (INR), neutrophil (NEUT), lymphocyte (LYMP), neutrophil lymphocyte rate (NLR), platelet (PLT), mean platelet volume (MPV) levels were analyzed in both groups. RNFL, Inferior RNFL (IRNFL), Superior RNFL (SRNFL), GCL++, CMT and CT were measured by swept source optical coherence tomography (OCT). The choroidal vascular index (CVI) was also obtained. Results: GGT (p=0.001), ALP (p<0.001), albumin (p<0.001), NEUT (p=0.046) and MPV (p<0.001) values were higher in the PBC group. INR (p=0.017) and PLT (p=0.027) values were lower in the PBC group. CMT (p=0.015), CT (p=0.002), and GCL++ (p<0.001) values were found lower in the PBC group. Conclusions: OCT analyzes revealed thinning in CMT, CT and GCL++ in patients with liver dysfunction. OCT analyzes should be evaluated during periodic ocular examinations of PBC patients.

Background: To determine the effectiveness of bone marrow-derived mesenchymal stem cell therapy on visual acuity and visual field in patients with retinitis pigmentosa. Objective: Stem cell treatment in retinitis pigmentosa provides improvement in visual acuity and visual field. Method: Forty-seven eyes of 27 patients diagnosed with retinitis pigmentosa were included in our study. Allogeneic bone marrow-derived mesenchymal stem cells were administered by deep subtenon injection. Complete routine ophthalmological examinations, optical coherence tomography (Zeiss, Cirrus HD-OCT) measurements, and visual field (Humphrey perimetry, 30-2) tests were performed on all patients before the treatment and on the 1st, 3rd, and 6th month after treatment. The best corrected visual acuities of the patients were determined by the Snellen chart and converted to logMAR. Visual evoked potential (VEP) and electroretinogram (ERG) examinations of the patients before the treatment and on the 6th month after the treatment were performed (Metrovision) data were compared. Results: Visual acuities were 0.74 ± 0.49 logMAR before treatment and 0.61 ± 0.46 logMAR after treatment. Visual acuity had a statistically significant increase (p <0.001). The visual field deviation was found to be -27.16 ± 5.77 dB before treatment and -26.59 ± 5.96 dB after treatment (p = 0.005). The ganglion cell layer was 46.26 ± 12.87 μm before treatment and 52.47 ± 12.26 μm after treatment (p = 0.003). There was a significant improvement in Pattern VEP 120º P100 amplitude compared to that before the treatment (4.43 ± 2.42 μV) and that after the treatment (5.09 ± 2.86 μV) (p = 0.013). ERG latency measurements were 18.33 ± 15.39 μV before treatment and 20.87 ± 18.64 μV after treatment for scotopic 0.01 (p = 0.02). ERG latency measurements for scotopic 3.0 were 20.75 ± 26.31 μV before treatment and 23.10 ± 28.60 μV after treatment (p = 0.014). Conclusion: Retinitis pigmentosa is a progressive, inherited disease that can result in severe vision loss. In retinitis pigmentosa, the application of bone marrow-derived mesenchymal stem cells by deep subtenon injection has positive effects on visual function. No systemic or ophthalmic side effects were detected in the patients during the 6-month follow-up period